PALISADE BIO, INC. (PALI) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001357459 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | $500,000 | $-10.6M | $-0.05 | Filing |
| Mar 31, 2026 | May 12, 2026 | $0 | $-9.6M | $-0.05 | Filing |
| Dec 31, 2025 | Mar 20, 2026 | $0 | $-8.9M | $1.13 | Filing |
| Sep 30, 2025 | Nov 10, 2025 | $0 | $-2.9M | $-0.38 | Filing |
| Jun 30, 2025 | Aug 11, 2025 | $0 | $-2.8M | $-0.58 | Filing |
| Mar 31, 2025 | May 12, 2025 | $0 | $-2.2M | $-0.47 | Filing |
| Dec 31, 2024 | Mar 24, 2025 | $0 | $-3.3M | $0.04 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | $0 | $-3.5M | $-2.32 | Filing |
What would PALISADE BIO, INC. have to report for its valuation to change?
At $1.41, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -28.6% a year, to $0.12. On that path the next quarter needs diluted EPS near $-0.27, against $-0.38 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -28.6% | -28.6% |
| EPS needed in final year | $0.12 | $0.12 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PALI goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.